Why Kolabtree
Getting started is quick and easy. No upfront fees
It’s free to request a service and invite bids from experts
Discuss requirements with the expert in detail before accepting statement of work from Kolabtree
Collaborate with the expert directly to get your work done the right way
Fund project when you hire the expert, but approve the deliverables only once work is done
Want to hire this expert for a project? Request a quote for free.
Profile Details
Create Project
★★★★★
☆☆☆☆☆
USD 250 /hr
Hire Dr. Morassa M.
United States
USD 250 /hr

Genomics & Diagnostics Product Strategy Consultant | Technical Due Diligence | NGS, cfDNA/NIPT, IVD

Profile Summary
Subject Matter Expertise
Services
Research Market Research
Consulting Business Strategy Consulting, Scientific and Technical Consulting, Regulatory Consulting
Product Development Product Evaluation, Product Validation, Quality Assurance & Control (QA/QC), Product Compliance , Concept Development, Product Launch Support
Work Experience

SVP, Product & Commercial Strategy

Swan Genomics

August 2024 - Present

Founder

M3 Advisory, LLC

January 2022 - Present

VP, Product Development & Scientific Operations

Encodia

December 2021 - April 2024

Senior Director, Genomic Applications & Collaborations

PacBio (formerly Omniome)

August 2017 - December 2021

Head of Product Care & Global Customer Support, cfDNA/ctDNA

Roche (United States)

2014 - 2017

Director, Technical Services

Ariosa

2012 - 2014

Education

PhD, Human Genetics & Molecular Biology

Johns Hopkins University

January 2006 - January 2011

PhD, Human Genetics & Molecular Biology

Johns Hopkins University

2006 - 2011

Certifications
  • New Product Development Professional (NPDP)

    Product Development and Management Association (PDMA)

    January 2021 - Present

Publications
JOURNAL ARTICLE
Cidado J, Wong HY, Rosen DM, Cimino-Mathews A, Garay JP, Fessler AG, Rasheed ZA, Hicks J, Cochran RL, Croessmann S, et al.(2016). Ki-67 is required for maintenance of cancer stem cells but not cell proliferation . Oncotarget.
Croessmann S, Wong HY, Zabransky DJ, Chu D, Mendonca J, Sharma A, Mohseni M, Rosen DM, Scharpf RB, Cidado J, et al.(2015). NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability . Proceedings of the National Academy of Sciences of the United States of America.
Blair BG, Wu X, Zahari MS, Mohseni M, Cidado J, Wong HY, Beaver JA, Cochran RL, Zabransky DJ, Croessmann S, et al.(2014). A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations . Proteomics.
Mohseni M, Cidado J, Croessmann S, Cravero K, Cimino-Mathews A, Wong HY, Scharpf R, Zabransky DJ, Abukhdeir AM, Garay JP, et al.(2014). MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers . Proceedings of the National Academy of Sciences of the United States of America.
Wu X, Renuse S, Sahasrabuddhe NA, Zahari MS, Chaerkady R, Kim MS, Nirujogi RS, Mohseni M, Kumar P, Raju R, et al.(2014). Activation of diverse signalling pathways by oncogenic PIK3CA mutations . Nature communications.
Juneau K, Bogard PE, Huang S, Mohseni M, Wang ET, Ryvkin P, Kingsley C, Struble CA, Oliphant A, Zahn JM(2014). Microarray-based cell-free DNA analysis improves noninvasive prenatal testing . Fetal diagnosis and therapy.
Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W, et al.(2013). Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation . Cancer research.
Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M, et al.(2012). The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation . Breast cancer research : BCR.
Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, et al.(2011). Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells . Proceedings of the National Academy of Sciences of the United States of America.
Higgins MJ, Beaver JA, Wong HY, Gustin JP, Lauring JD, Garay JP, Konishi H, Mohseni M, Wang GM, Cidado J, et al.(2011). PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells . Cancer biology & therapy.
Mohseni M, Park BH(2010). PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001 . The Journal of clinical investigation.
Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, Garay JP, Mohseni M, Wang GM, Higgins MJ, et al.(2010). Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations . Oncogene.
Karnan S, Mohseni M, Konishi Y, Tamaki A, Hosokawa Y, Park BH, Konishi H(2009). Controversial BRCA1 allelotypes in commonly used breast cancer cell lines . Breast cancer research and treatment.
Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, et al.(2009). Knockin of mutant PIK3CA activates multiple oncogenic pathways . Proceedings of the National Academy of Sciences of the United States of America.